[1] Rubens RD.Bone metastases-incidence and complications.In Rubens RD,Mundy GR.Cancer and the skeleton.London:Martin Dunitz,2000.33-42.
[2] Schirrmeister H,Buck A,Guhlmann A,et al.Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodiumfluoride PET..Thyroid,2001,11(7):677-683.
[3] Schirrmeister H,Guhlmann A,Elsner K,et al.Sensitivity in detecting osseous lesions depends on anatomic localization:planar bone scintigraphy versus 18F PET.J Nucl Med,1999,40(10):1623-1629.
[4] Hetzel M,Arslandemir C,Konig HH,et al.F-18 NaF PET for detection of bone metastases in lung cancer:accuracy,costeffectiveness and impact on patient management.J Bone Miner Res,2003,18(12):2206-2214.
[5] Schirrmeister H,Glatting G,Hetzel J,et al.Prospective evaluation of the clinical value ofplanar bone scans,SPECT and (18)F-labeled NaF PET in newly diagnosed lung cancer.J Nucl Med,2001,42(12):1800-1804.
[6] Schirrmeisier H,Buck AK,Bergmann L,et al.PET for staging of solitary plasmacytoma.Cancer Biother Radiopharm,2003,18(5):841-845.
[7] Wu HC,Yen RF,Shen YY,et al.Comparing whole body 18F-2-deoxyglucose PET and 99mTc MDP bone scan to detect bone metastases in patients with renal cell carcinomas-a preliminary report.J Cancer Res Clin Oncol,2002,128(9):503-506.
[8] Marom EM,McAdams HP,Erasmus JJ,et al.Staging non-small cell lung cancer with whole-body PET.Radiology,1999,212(3):803-809.
[9] Cook GJ,Houston S,Rubens R,et al.Detection of bone metastases in breast cancer by 18F-FDG PET:differing metabolic activity in osteoblastic and osteolytic lesions.J Clin Oncol,1998,16(10):3375-3379.
[10] Franzius C,Sciuk J,Daldrup-Link HE,et al.FDG PET for detection of osseous metastases from malignant primary bone tumours:comparison with bone scintigraphy.Eur J Nucl Med,2000,27(9):1305-1311.
[11] Gallowitsch H J,Kresnik E,Gasser J,et al.F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma:A comparison to conventional imaging.Invest Radiol,2003,38(5):250-256.
[12] Jadvar H,Pinski JK,Conti PS.FDG PET in suspected recurrent and metastatic prostate cancer.Oncol Rep,2003,10(5):1485-1488.
[13] Gayed I,Vu T,Johnson M,et al.Comparison of bone and 2-dooxy-2-[18F]fluoro-D-glucose PET in the evaluation of bony metastases inlung cancer.Mol Imaging Biol,2003,5(1):26-31.
[14] Bury T,Barreto A,Daenen F,et al.Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.Eur J Nucl Med,1998,25(9):1244-1247.
[15] Stafford SE,Gralow JR,Schubert EK,et al.Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.Acad Radiol,2002,9(8):913-921.
[16] Fogelman I,Cook G,Israel O,et al.Positron emission tomography and bone metastaese.Semin Nucl Med,2005,35(2):135-142.
[17] Israel O,Mor M,Guralnik L,et al.Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?.J Nucl Med,2004,45(12):2045-2051.
[18] Even-Sapir E,Metser U,Flusser G,et al.Assessment of malignant skeletal disease:initial experience with 18F-fluoride PET/CT and comparison between 11C-fluoride PET and 18F-fluoride PET/CT.J Nucl Med,2004,45(2):272-278.
[19] Ho-Shon I,Fogelman I.F-18 FDG PET and benign fractures.Clin Nucl Med,2003,28(3):171-175.